Accreditation, setting and experience as indicators to assure quality in oncology biomarker testing laboratories
Open Access
- 24 August 2018
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 119 (5) , 605-614
Abstract
Predictive biomarkers allow clinicians to optimise cancer treatment decisions. Therefore, molecular biomarker test results need to be accurate and swiftly available. To ensure quality of oncology biomarker testing, external quality assessments (EQA) for somatic variant analyses were organised. This study hypothesised whether laboratory characteristics influence the performance of laboratories and whether these can be imposed before authorisation of biomarker testing. Longitudinal EQA data from the European Society of Pathology were available over six (metastatic colorectal cancer) and four years (non-small cell lung cancer), including the percentage of analysis errors and technical failures, and information on laboratory characteristics (accreditation status, laboratory setting, number of samples analysed and detection method). Statistical models for repeated measurements were used to analyse the association between the EQA results and the laboratory characteristics. Laboratory accreditation was associated with fewer analysis errors in early stages of biomarker introduction into the laboratory. Analysing more samples, or university and research laboratories showed better performance. Changing the detection method did not have an effect. The indicators support the clinicians in choosing molecular pathology laboratories by improving quality assurance and guaranteeing patient safety. Accreditation of laboratories, centralisation of biomarker testing or a university and research setting should be stimulated.Keywords
This publication has 24 references indexed in Scilit:
- The Relevance of External Quality Assessment for Molecular Testing for ALK Positive Non-Small Cell Lung Cancer: Results from Two Pilot Rounds Show Room for OptimizationPLOS ONE, 2014
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal CancerNew England Journal of Medicine, 2013
- Improvement in the quality of molecular analysis of EGFR in non-small-cell lung cancer detected by three rounds of external quality assessmentJournal of Clinical Pathology, 2013
- Guideline on the requirements of external quality assessment programs in molecular pathologyVirchows Archiv, 2012
- Randomized Trial of Radiation Therapy Plus Procarbazine, Lomustine, and Vincristine Chemotherapy for Supratentorial Adult Low-Grade Glioma: Initial Results of RTOG 9802Journal of Clinical Oncology, 2012
- Tumour molecular profiling for deciding therapy—the French initiativeNature Reviews Clinical Oncology, 2012
- Quality assurance practices in Europe: a survey of molecular genetic testing laboratoriesEuropean Journal of Human Genetics, 2012
- ROS1 Rearrangements Define a Unique Molecular Class of Lung CancersJournal of Clinical Oncology, 2012
- Critical comments for roles of biomarkers in the diagnosis and treatment of cancerCancer Treatment Reviews, 2012
- EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapyJournal of Clinical Pathology, 2011